|
|
 Previous Article | Table of Contents | Next Article 
Blood, Vol. 96 No. 2 (July 15), 2000:
pp. 594-600
Impaired binding of perforin on the surface of tumor cells is a
cause of target cell resistance against cytotoxic effector cells
Christof Lehmann,
Matthias Zeis,
Norbert Schmitz, and
Lutz Uharek
From the Department of Internal Medicine II, University of Kiel,
Kiel, Germany.
Exocytosis of perforin, subsequent binding of perforin to the target
cell membrane, and formation of lytic pores form an important pathway
involved in the induction of tumor cell death by cytotoxic effector
cells. Here we describe a novel escape mechanism employed by tumor
cells to protect themselves from granule-mediated cell death: We were
able to demonstrate that the resistance of the human leukemia cell line
ML-2 to natural killer (NK)-cell-mediated killing is not caused by
impaired NK-cell activation but by resistance against effector
molecules contained in the granules of cytotoxic cells. No resistance
was observed against other pore-forming agents like complement and
streptolysin O. By using the NK-susceptible leukemia cell line K562, we
could show that the induction of cell death by cytotoxic granules can
be blocked completely by anti-perforin antibodies, indicating that
perforin is essentially involved in this process. Flow cytometric data
revealed that an impaired binding of perforin on the tumor cell
membrane is mainly responsible for target cell resistance, because
perforin turned out to bind well on K562 cells but is not able to
attach to the surface of ML-2 cells. After impaired binding of perforin
was identified as a potential mechanism of tumor cell resistance,
leukemia cells from 6 patients with acute myeloid leukemia (AML) were
examined. As predicted, AML cells that failed to bind perforin on their
surface demonstrated complete resistance toward NK-cell-mediated
cytotoxicity. Thus, perforin resistance could represent an important
tumor escape mechanism that should be considered when cytotoxic
effector cells are used for cellular immunotherapy.
 CiteULike  Connotea  Del.icio.us  Digg  Reddit  Technorati What's this?
Related Letters in Blood Online:
-
Flow cytometry cannot assess surface binding of perforin to target cells
- Sunil S. Metkar, M. Aguilar-Santelises, Baikun Wang, Christopher J. Froelich, Christof Lehmann, and Lutz Uharek
Blood 2001 97: 2181-2183.
[Full Text]
[PDF]
-
Risk for cytomegalovirus disease in patients receiving polymerase chain reaction-based preemptive antiviral therapy after allogeneic stem cell transplantation depends on transplantation modality
- Holger Hebart, Wolfram Brugger, Ulrich Grigoleit, Barbara Gscheidle, Juergen Loeffler, Hansjörg Schäfer, Lothar Kanz, Hermann Einsele, and Christian Sinzger
Blood 2001 97: 2183-2185.
[Full Text]
[PDF]
This article has been cited by other articles:
|
|
|
|
 
K. Suemori, H. Fujiwara, T. Ochi, T. Ogawa, M. Matsuoka, T. Matsumoto, J.-M. Mesnard, and M. Yasukawa
HBZ is an immunogenic protein, but not a target antigen for human T-cell leukemia virus type 1-specific cytotoxic T lymphocytes
J. Gen. Virol.,
August 1, 2009;
90(8):
1806 - 1811.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
Y. KAWAGUCHI, K. KONO, Y. MIZUKAMI, K. MIMURA, and H. FUJII
Mechanisms of Escape from Trastuzumab-mediated ADCC in Esophageal Squamous Cell Carcinoma: Relation to Susceptibility to Perforin-granzyme
Anticancer Res,
June 1, 2009;
29(6):
2137 - 2146.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. S. Czuczman, S. Olejniczak, A. Gowda, A. Kotowski, A. Binder, H. Kaur, J. Knight, P. Starostik, J. Deans, and F. J. Hernandez-Ilizaliturri
Acquirement of Rituximab Resistance in Lymphoma Cell Lines Is Associated with Both Global CD20 Gene and Protein Down-Regulation Regulated at the Pretranscriptional and Posttranscriptional Levels
Clin. Cancer Res.,
March 1, 2008;
14(5):
1561 - 1570.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
T. Azuma, T. Otsuki, K. Kuzushima, C. J. Froelich, S. Fujita, and M. Yasukawa
Myeloma Cells Are Highly Sensitive to the Granule Exocytosis Pathway Mediated by WT1-Specific Cytotoxic T Lymphocytes
Clin. Cancer Res.,
November 1, 2004;
10(21):
7402 - 7412.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
Y.-W. Hsiao, K.-W. Liao, S.-W. Hung, and R.-M. Chu
Tumor-Infiltrating Lymphocyte Secretion of IL-6 Antagonizes Tumor-Derived TGF-{beta}1 and Restores the Lymphokine-Activated Killing Activity
J. Immunol.,
February 1, 2004;
172(3):
1508 - 1514.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
H.-J. Kolb, C. Schmid, A. J. Barrett, and D. J. Schendel
Graft-versus-leukemia reactions in allogeneic chimeras
Blood,
February 1, 2004;
103(3):
767 - 776.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
F. J. Hernandez-Ilizaliturri, V. Jupudy, J. Ostberg, E. Oflazoglu, A. Huberman, E. Repasky, and M. S. Czuczman
Neutrophils Contribute to the Biological Antitumor Activity of Rituximab in a Non-Hodgkin's Lymphoma Severe Combined Immunodeficiency Mouse Model
Clin. Cancer Res.,
December 1, 2003;
9(16):
5866 - 5873.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
J. Odeberg, H. Browne, S. Metkar, C. J. Froelich, L. Branden, D. Cosman, and C. Soderberg-Naucler
The Human Cytomegalovirus Protein UL16 Mediates Increased Resistance to Natural Killer Cell Cytotoxicity through Resistance to Cytolytic Proteins
J. Virol.,
April 15, 2003;
77(8):
4539 - 4545.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
N. J. Wandersee, C. S. Birkenmeier, D. M. Bodine, N. Mohandas, and J. E. Barker
Mutations in the murine erythroid alpha -spectrin gene alter spectrin mRNA and protein levels and spectrin incorporation into the red blood cell membrane skeleton
Blood,
January 1, 2003;
101(1):
325 - 330.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
K. N. Balaji, N. Schaschke, W. Machleidt, M. Catalfamo, and P. A. Henkart
Surface Cathepsin B Protects Cytotoxic Lymphocytes from Self-destruction after Degranulation
J. Exp. Med.,
August 19, 2002;
196(4):
493 - 503.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
S. Nagakura, S. Ishihara, D. E. Dunn, J.-i. Nishimura, T. Kawaguchi, K. Horikawa, M. Hidaka, T. Kagimoto, N. Eto, H. Mitsuya, et al.
Decreased susceptibility of leukemic cells with PIG-A mutation to natural killer cells in vitro
Blood,
July 18, 2002;
100(3):
1031 - 1037.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
F. H. Igney and P. H. Krammer
Immune escape of tumors: apoptosis resistance and tumor counterattack
J. Leukoc. Biol.,
June 1, 2002;
71(6):
907 - 920.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. Yasukawa, H. Ohminami, K. Kojima, T. Hato, A. Hasegawa, T. Takahashi, H. Hirai, and S. Fujita
HLA class II-restricted antigen presentation of endogenous bcr-abl fusion protein by chronic myelogenous leukemia-derived dendritic cells to CD4+ T lymphocytes
Blood,
September 1, 2001;
98(5):
1498 - 1505.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. I. Kafrouni, G. R. Brown, and D. L. Thiele
Virally Infected Hepatocytes Are Resistant to Perforin-Dependent CTL Effector Mechanisms
J. Immunol.,
August 1, 2001;
167(3):
1566 - 1574.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. J. Smyth, J. M. Kelly, V. R. Sutton, J. E. Davis, K. A. Browne, T. J. Sayers, and J. A. Trapani
Unlocking the secrets of cytotoxic granule proteins
J. Leukoc. Biol.,
July 1, 2001;
70(1):
18 - 29.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
S. S. Metkar, M. Aguilar-Santelises, B. Wang, C. J. Froelich, C. Lehmann, and L. Uharek
Flow cytometry cannot assess surface binding of perforin to target cells
Blood,
April 1, 2001;
97(7):
2181 - 2183.
[Full Text]
[PDF]
|
|
|
|
|
